Quantum Genomics Corp (QGC) names Lionel Ségard CEO

Ségard, former Chief Executive Officer of Inserm-Transfert, will lead QGC Development of promising Drug Advances in Europe into Innovative Human Therapeutics

Jersey City, New Jersey-June 6, 2006 - Quantum Genomics Corp (QGC), a global biotechnology company seeking to transform the discoveries and developments of academic research into breakthrough treatments for human disease, announced today that it has appointed Lionel Ségard as Chief Executive Officer.

QGC's business is identifying and developing innovative human health discovery projects in areas where there is a significant unmet medical need. The company intends to zero in on the many high-potential academic discoveries that never make it beyond the academic research laboratory, and provide the know-how that academics require to bring their discoveries to market.

QGC has already earmarked EUR 3 million to finance early stage projects. This will enable QGC to begin the identification and selection of breakthrough research projects in Europe, as well as to recruit a range of specialists to provide the required management, scientific and other expertise.

"Lionel Ségard is a leading expert in sourcing, developing, and financing innovative biotechnology projects," said Jonathan McCann, board member of QGC. "Lionel's experience in building teams of experts from a variety of backgrounds is a tremendous asset to QGC."

"QGC is a new type of company that has a huge growth potential," said Lionel Ségard. "I am proud to apply my experience for the benefit of the company and to bring products to market that would not otherwise exist. We expect to develop new treatments not only for common diseases but also for orphan diseases. We are already examining a number of projects and plan to start development of these projects before year-end."

A qualified biochemist, Lionel Ségard, 38, was CEO of Inserm-Transfert, Inserm's technology transfer arm (Inserm is the French National Institute of Health), until March 2006. In this position, he made a major contribution to the transfer of technology between research and industry in charge of a team which arranged financing for twelve start-ups that raised more than EUR 80 million, created a dedicated investment company and provided the management for more than 20 European research projects, with a total cost in excess of EUR 500 million.

He is also a founder member of France's Strategic Council for Innovation where he was secretary general from 2003-2005. The Council's goal is to boost French efforts in the field of research and advanced technologies and includes key individuals from France's science, industry and financial community. Ségard began his career at IBM as a scientist. From 1999-2002, he was CEO of the French subsidiary of a US information technology company, 24/7 Media (NASDAQ: TFSM). In parallel, he was co-founder of Eurobiobiz, a company that worked with the European Commission to help create and develop European biotechnology companies and advise investment funds.

About Quantum Genomics Corp. (QGC): www.Quantum-Genomics.com
Quantum Genomics Corp. (QGC), Jersey City, New Jersey, is a global biotechnology company seeking to transform the discoveries and developments of academic research into breakthrough treatments for human disease. The company has unique expertise in the detection and selection of highly promising life science projects. It co-develops products with academic teams. It also develops public/private partnerships to speed up the process of research/development to turn basic research into products. QGC initial areas of interest and expertise are in cardiovascular diseases, neurology, and metabolism-related diseases. QGC's strategic alliances and business partnerships will include disease-oriented therapeutic collaborations, technology transfer-agreements, and marketing/licensing agreements in the fields of recombinant proteins, monoclonal antibodies, and advanced chemical compounds.

For more information, please contact:

Andrew Lloyd & Associates
Heidi Thompson / Neil Hunter
Tel. +44 1273 675100
heidi@ala.com  / neil@ala.com